Literature DB >> 31338700

Antineutrophil cytoplasmic antibodies and their relationship with disease activity and presence of staphylococcal superantigens in nasal swabs in patients having granulomatosis with polyangiitis: results of a study involving 115 patients from a single center.

Justyna Fijolek1, E Wiatr2, V Petroniec3, E Augustynowicz-Kopec3, M Bednarek4, D Gawryluk2, K Roszkowski-Sliz2.   

Abstract

OBJECTIVE: Antineutrophil cytoplasmic antibodies (ANCAs) are considered a risk factor for granulomatosis with polyangiitis (GPA) exacerbation, especially when staphylococcal superantigens (SAgs) are present in nasal swabs. Their role in monitoring disease activity remains controversial. This study determined the relationship of ANCAs with disease activity and presence of SAgs in GPA patients.
METHODS: Among a total of 115 GPA patients hospitalized in the period 2009-2016, we investigated the presence of SAgs and ANCA concentration. Blood samples and nasal swabs were taken at each visit (referred further to as episodes). Disease activity was assessed using the Birmingham Vasculitis Activity Score (BVAS).
RESULTS: We analyzed 362 episodes. ANCAs were detected in 215 (59.4%), while SAgs were detected in 126 (34.8%) episodes. We found a significant correlation between the presence of ANCAs and disease activity (p = 0.0032), as well as between their level and GPA severity (r = 0.25363, p = 0.000001). We also determined that an ANCA values ≥ 138 Ru/ml were an indicator of active disease with high specificity and low sensitivity (84.4% and 37.3%, respectively). The relationship between ANCA presence and the presence of SAgs was not confirmed; however, when SAgs were analyzed based on the different types, ANCA levels were found to be significantly higher in the group with SAg type B (p = 0.031).
CONCLUSIONS: There was no detectable evidence for the association between ANCA level and the presence of SAgs. Although monitoring ANCA levels as a marker of disease activity may be clinically relevant, GPA management cannot proceed on the basis of ANCA levels alone. Key Points • ANCA concentration usually correlates with GPA activity, although in half of patients, ANCAs persist despite effective treatment and clinical remission. • ANCA values of 138 Ru/ml seem to be an indicator of active disease with high specificity, but low sensitivity. • Although there is a relevance for ANCA monitoring as a marker of disease activity, GPA management cannot be based on ANCA levels alone. • The suspected clinical correlation between ANCA formation and SAg presence in nasal swabs is not obvious and requires further investigations.

Entities:  

Keywords:  Antineutrophil cytoplasmic antibodies; Disease activity; Granulomatosis with polyangiitis; Staphylococcal superantigens

Year:  2019        PMID: 31338700     DOI: 10.1007/s10067-019-04693-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  43 in total

1.  Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study.

Authors:  T Girard; A Mahr; L H Noël; J F Cordier; P Lesavre; M H André; L Guillevin
Journal:  Rheumatology (Oxford)       Date:  2001-02       Impact factor: 7.580

2.  Neutrophil extracellular traps kill bacteria.

Authors:  Volker Brinkmann; Ulrike Reichard; Christian Goosmann; Beatrix Fauler; Yvonne Uhlemann; David S Weiss; Yvette Weinrauch; Arturo Zychlinsky
Journal:  Science       Date:  2004-03-05       Impact factor: 47.728

3.  A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Rachel B Jones; Alastair J Ferraro; Afzal N Chaudhry; Paul Brogan; Alan D Salama; Kenneth G C Smith; Caroline O S Savage; David R W Jayne
Journal:  Arthritis Rheum       Date:  2009-07

Review 4.  Update on the epidemiology, risk factors, and outcomes of systemic vasculitides.

Authors:  Alvise Berti; Christian Dejaco
Journal:  Best Pract Res Clin Rheumatol       Date:  2018-11-02       Impact factor: 4.098

Review 5.  Pathogenesis of ANCA-associated vasculitis: An update.

Authors:  Pierre-André Jarrot; Gilles Kaplanski
Journal:  Autoimmun Rev       Date:  2016-03-09       Impact factor: 9.754

Review 6.  Predictors of Poor Outcome in ANCA-Associated Vasculitis (AAV).

Authors:  Luis E Vega; Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2016-12       Impact factor: 4.592

7.  Linked help from bacterial proteins drives autoantibody production in small vessel vasculitis.

Authors:  David B G Oliveira
Journal:  Med Hypotheses       Date:  2018-01-17       Impact factor: 1.538

Review 8.  The relation between Staphylococcus aureus and Wegener's granulomatosis: current knowledge and future directions.

Authors:  E R Popa; J W Cohen Tervaert
Journal:  Intern Med       Date:  2003-09       Impact factor: 1.271

9.  Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.

Authors:  R A Luqmani; P A Bacon; R J Moots; B A Janssen; A Pall; P Emery; C Savage; D Adu
Journal:  QJM       Date:  1994-11

Review 10.  Staphylococcus aureus and Wegener's granulomatosis.

Authors:  Eliane R Popa; Coen A Stegeman; Cees G M Kallenberg; Jan Willem Cohen Tervaert
Journal:  Arthritis Res       Date:  2001-10-26
View more
  3 in total

Review 1.  Biomarkers in ANCA-Associated Vasculitis: Potential Pitfalls and Future Prospects.

Authors:  Adam D Morris; Anthony W Rowbottom; Francis L Martin; Alexander Woywodt; Ajay P Dhaygude
Journal:  Kidney360       Date:  2021-01-19

2.  Diagnostic accuracy of antineutrophil cytoplasmic antibodies (ANCA) in predicting relapses of ANCA-associated vasculitis: systematic review and meta-analysis.

Authors:  Pankti Mehta; Anu Balakrishnan; Sanat Phatak; Mona Pathak; Sakir Ahmed
Journal:  Rheumatol Int       Date:  2022-08-30       Impact factor: 3.580

3.  Lack of elevated pre-ART elastase-ANCA levels in patients developing TB-IRIS.

Authors:  Odin Goovaerts; Marguerite Massinga-Loembé; Pascale Ondoa; Ann Ceulemans; William Worodria; Harriet Mayanja-Kizza; Robert Colebunders; Luc Kestens
Journal:  PLoS One       Date:  2020-12-31       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.